ACADIA Pharmaceuticals Inc
ACADHealthcare|Biotechnology|USA
$26.22
-0.19 (-0.72%)
DCF (FCF)
$4.73
Tangible Book
$6.67
Graham Number
$18.18
Earnings Power
$5.25
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1241.21,
1394.37,
1577.1,
1653.48,
1807.19
],
"ebit_estimate": [
50.07,
150.6,
288.65,
350.86,
541.11
],
"ebitda_estimate": [
68.02,
182.77,
358.63,
503.9,
685.05
],
"net_income_estimate": [
66.38,
152.91,
280.28,
321.33,
438.89
],
"per_share_eps_estimate": [
0.4,
0.79,
1.51,
1.79,
2.65
],
"eps_nri_estimate": [
0.38,
0.84,
1.48,
1.76,
2.59
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
7.63,
8.79,
10.57,
15.03,
18.52
],
"pretax_income_estimate": [
82.84,
181.99,
329.25,
460.66,
593.25
],
"operating_cash_flow_per_share_estimate": [
0.83,
1.09,
2.33,
2.76,
3.5
],
"roa_estimate": [
5.5,
12.35,
16.6,
9.1,
10.8
],
"roe_estimate": [
5.68,
12.4,
18.29,
16.9,
18.35
],
"gross_margin_estimate": [
91.9,
91.97,
92.16,
91.36,
91.11
],
"operating_cash_flow_estimate": [
143,
188.94,
401.97,
475.81,
604.47
],
"pettm_estimate": [
65.06,
33.32,
17.36,
14.66,
9.91
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "13.61",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 13.61,
"future_ebit_estimate_growth": 51.29,
"future_ebitda_estimate_growth": 54.64,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 40.16,
"future_book_value_per_share_estimate_growth": 13.55,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 0.16,
"future_operating_cash_flow_per_share_estimate_growth": 50.77
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
296.04,
325.59,
351.02,
321.7,
344.4,
369.3,
396.4
],
"ebit_estimate": [
6.11,
22.25,
28.45,
-20,
39.1,
64,
38.5
],
"ebitda_estimate": [
10.02,
29.42,
35.87,
-16.3,
42.8,
67.7,
42.2
],
"net_income_estimate": [
9.83,
24.43,
30.76,
-15.4,
31.9,
51.8,
31.4
],
"per_share_eps_estimate": [
0.07,
0.14,
0.17,
-0.09,
0.18,
0.3,
0.18
],
"eps_nri_estimate": [
0.06,
0.13,
0.17,
0.06,
0.2,
0.27,
0.22
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
7.31,
7.54,
7.79,
7.8,
8.09,
8.49,
8.77
],
"pretax_income_estimate": [
12.44,
29.03,
36.36,
-19.3,
39.9,
64.7,
39.3
],
"operating_cash_flow_per_share_estimate": [
0.25,
0.3,
0.26,
0.08,
0.22,
0.32,
0.19
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-3.29,
5.77,
6.03,
-1.2,
2.4,
3.7,
2.2
],
"gross_margin_estimate": [
92.72,
92.66,
92.77,
91.4,
91.2,
91,
90.7
],
"operating_cash_flow_estimate": [
43.18,
51.81,
44.9,
13.82,
38,
55.27,
32.81
],
"pettm_estimate": [
89.18,
65.55,
46.49,
46,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "13.61",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 13.61,
"future_ebit_estimate_growth": 51.29,
"future_ebitda_estimate_growth": 54.64,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 40.16,
"future_book_value_per_share_estimate_growth": 13.55,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 0.16,
"future_operating_cash_flow_per_share_estimate_growth": 50.77
}